fda tirzepatide weight loss approval for Zepbound: FSU researcher available for context on newly approved treatment Tirzepatide for Weight Loss Receives

Int J Obes 47 , 677685 (2023)

The UKs drug regulator has cleared a higher-strength dose of the weight-loss injection Wegovy, as demand for the treatment is expected to rise sharply

Other common digestive side effects include: Vomiting (common: may affect up to 1 in 10 people) Diarrhoea (very common: affects more than 1 in 10 people) Constipation (common: may affect up to 1 in 10 people) Abdominal pain or discomfort (common: may affect up to 1 in 10 people) Bloating and feelings of excessive fullness particularly noticeable after meals Reduced appetite (very common: affects more than 1 in 10 people) These side effects are generally most pronounced when starting Ozempic or increasing the dose , and they often improve over time as your body adjusts to the medication

Hazard ratios (HRs), 95% confidence intervals (CIs) and p values for stroke were calculated using a Cox proportional hazards model, with DPP4i as the reference group